Drug intelligence / Profile preview

Repaircell

Development stage: Phase 1
Lead developer: Anterogen
Modality: Cell Therapies
Administration: Subcutaneous

Overview

Repaircell (ANT-adip-AL) is a biological drug composed of allogenic differentiated adipocytes. These adipocytes are produced using established techniques, including harvesting cells from lipoaspirates obtained from healthy donors, expanding adipose tissue-derived stem cells, and differentiating them into pure and immature adipocytes. It is being developed by Anterogen Co., Ltd.

Beyond the preview

Go deeper on Repaircell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Repaircell.

Explore the full profile